Livagen vs Cartalax
Side-by-side comparison of Livagen and Cartalax: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Livagen
Cartalax
Livagen
Livagen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "liver bioregulator" intended to…
No vendor price on file.
Full Livagen profileCartalax
Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "cartilage bioregulator" intended to…
Lowest listed price: $58.85 across 3 listings
Full Cartalax profileSide-by-side comparison
| Attribute | Livagen | Cartalax |
|---|---|---|
| Category | Recovery | Recovery |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | Mechanism of Action Livagen's proposed mechanism is the standard Khavinson short-peptide bioregulator model applied to hepatic tissue. The framework, developed at the St. Petersburg Institute of Bioregulation and Gerontology across roughly 35 years, proposes… | Mechanism of Action Cartalax's proposed mechanism is the Khavinson short-peptide framework applied to cartilage: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing chondrocyte-favourable transcriptional shifts.… |
| Half-Life | — | No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured. |
| Typical Dose Range | 20 mg oral/sublingual capsule once daily for 10 consecutive days per cycle (or 2-5 mg subcutaneous daily using synthetic peptide); 60-90 day washout between cycles | 20 mg oral/sublingual once daily for 10 days; 60-90 day washout |
| Dosing Frequency | — | Once daily |
| Administration | — | — |
| Side Effects | Side Effects and Safety Livagen has been administered to humans and rodents in Russian studies for roughly 25 years with a reassuringly sparse side-effect literature — but that literature is also extremely small, unblinded, and biased toward reporting positive… | Side Effects and Safety Cartalax has been used in Russian clinical settings for roughly 20 years with a sparse adverse-event literature — reassuring in direction, insufficient for confident pharmacovigilance. Reported short-term adverse effects -… |
| Molecular Weight | ~461.5 Da (C18H31N5O9) | 333.29 g/mol |
| Common Vial Sizes | — | — |
Price History
3 data points- Ion Peptide
- Disguised Alpha
- LB
Livagen: potential benefits
- Liver tissue repair and regeneration
- Enhanced detoxification capacity
- Hepatocyte function normalization
- Liver anti-aging support
Cartalax: potential benefits
- Joint and cartilage repair support
- Connective tissue maintenance
- Anti-aging effects on musculoskeletal system
- Improved joint mobility
Frequently asked
What's the difference between Livagen and Cartalax?
Livagen is a recovery that mechanism of action livagen's proposed mechanism is the standard khavinson short-peptide bioregulator model applied to hepatic tissue. the framework, developed at the st.…. Cartalax is a recovery that mechanism of action cartalax's proposed mechanism is the khavinson short-peptide framework applied to cartilage: passive membrane permeation, nuclear import, and sequence-selective…. The two differ in mechanism, half-life (not reported vs No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured.), and typical dose range.
Which has the longer half-life, Livagen or Cartalax?
Livagen has a half-life of not reported. Cartalax has a half-life of No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Livagen and Cartalax?
Stacking depends on mechanism overlap, safety profile, and goals. Livagen and Cartalax should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Livagen or Cartalax
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.